Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 7/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.33 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | DBH | P09172 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8143882 | 0.87 | KDM4E (0.42) | KDM4ELMNAFTOAPPMAPK1 | |
| SCHEMBL9625503 | 0.86 | KDM4E (0.55) | KDM4ELMNAFTOAPPMAPK1 | |
| SCHEMBL22449893 | 0.78 | KDM4E (0.47) | KDM4ELMNAFTOAPPMAPK1 | |
| SCHEMBL7136835 | 0.76 | KDM4E (0.44) | KDM4ELMNAFTOAPP | |
| SCHEMBL6196974 | 0.75 | KDM4E (0.49) | KDM4ELMNAFTOAPPMAPK1 | |
| SCHEMBL6195700 | 0.74 | LMNA (0.43) | KDM4ELMNAFTOAPPMAPK1 | |
| SCHEMBL6196526 | 0.72 | KDM4E (0.41) | KDM4ELMNAFTOAPPALOX5 | |
| SCHEMBL6197109 | 0.72 | DBH (0.41) | KDM4ELMNAFTOAPPMAOA | |
| SCHEMBL6194369 | 0.72 | KDM4E (0.41) | KDM4ELMNAFTOAPPMAPK1 | |
| SCHEMBL6196007 | 0.72 | KDM4E (0.41) | KDM4ELMNAFTOAPPMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506911-B2 | Reacting a 2-(1-hydroxyalkyl)-3-hydroxypyran-4(1H)one compound with benzaldehyde dimethyl acetal to form 8-oxo-4,8-dihydro-2-phenyl-4h(3,2-d)-m-dioxin, reacting it with an amine compound to form an intermediate, then reducing | BTG INTERNATIONAL LIMITED (GB) | 2003-01-14 | — | — | US | disclosed |
| EP-0984934-B1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNAT LTD COMPANY NO 26 (GB) | 2003-01-08 | — | — | EP | disclosed |
| US-6448273-B1 | SUCH AS 2,6-DIMETHOXYMETHYL-1-METHYL-3-BENZYLOXPYRIDIN-4(1H)-ONE; TREATING DISORDERS ASSOCIATED WITH IRON DISTRIBUTION AND IRON DEPENDANT PARASITES; REDUCED LEVELS OF ACTIVE AGENT; SELECTIVE TARGETING TO TISSUES AND LIVER; METABOLIC STABILITY | BTG INTERNATIONAL LIMITED (GB) | 2002-09-10 | — | — | US | disclosed |
| US-20020068758-A1 | Novel orally active iron (III) chelators | BTG INTERNATIONAL LIMITED. | 2002-06-06 | — | — | US | disclosed |
| US-6335353-B1 | 3-HYDROXYPYRIDIN-4-ONE DERIVATIVE; IRON DEFICIENCY ANEMIA AND THALASSEMIA TREATMENT | BTG INTERNATIONAL LIMITED (GB) | 2002-01-01 | — | — | US | disclosed |
| EP-0984934-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (Company No. 2664412) (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054138-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (GB) | 1998-12-03 | — | — | WO | disclosed |
| WO-1992012131-A1 | 3-HYDROXYPYRIDIN-4-ONE DERIVATIVES AS PHARMACEUTICAL COMPOSITIONS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1992-07-23 | — | — | WO | disclosed |
| EP-0494754-A1 | 3-hydroxypyridin-4-one derivatives as pharmaceutical compositions | BRITISH TECHNOLOGY GROUP LTD (GB) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068758-A1 | Novel orally active iron (III) chelators | HAMP, HRH2, GRHPR | KDM4E 1012/4885LMNA 2634/4885FTO 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.